- Repligen | Inspiring advances in bioprocessing
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its CTech™ SoloVPE ® PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers
- About Repligen
The innovative bioprocessing products manufactured by Repligen are designed to address these important needs of biopharmaceutical manufacturers in an increasingly competitive environment
- Products - Repligen
Whether you are in fed-batch, hybrid continuous or full continuous mode, or working with therapeutic proteins, gene therapy or vaccines, you can use leading edge solutions from Repligen to streamline your processes and cut your manufacturing costs
- Careers - Repligen
At Repligen, we provide opportunities for conversation about DEI, offer DEI education resources, encourage allyship, and invest time and energy into developing diverse talent
- Repligen Corporation - Press Releases
Repligen Corporation to Present at Upcoming May Investor Conferences Download Repligen Corporation to Present at Upcoming May Investor Conferences in PDF format" (opens in new window)
- Repligen Corporation - Investor Relations
Investor Relations About Repligen We are a US-based, global developer and manufacturer of highly innovative bioprocessing tools and technologies We provide advanced systems and solutions that enable efficiencies and help set new standards for the way biological drugs are manufactured
- News Room - Repligen
Stay up-to-date with the latest news from Repligen, including company announcements, product launches, industry insights, and upcoming events Explore how we’re advancing innovation in bioprocessing and shaping the future of therapeutic manufacturing
- Leadership - Repligen
George A Scott, Jr joined Repligen in April 2024 as Vice President, Global Head of Legal In this role he leads the global legal operations for the Company and drives its strategic direction in support of Repligen’s mission
|